Linked Life Data

15026254

Source:http://linkedlifedata.com/resource/pubmed/id/15026254

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2004-3-17
pubmed:abstractText
Recent studies have implicated alpha-synuclein (alpha-S) in the pathogenesis of Parkinson's disease (PD). The mechanisms underlying PD are not completely understood; however, mitochondrial complex I inhibition and oxidative injury may be involved. Because the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a potent complex I inhibitor that can cause oxidative injury and mimic many aspects of PD in treated animals, we sought to determine whether the overexpression of alpha-S in transgenic (tg) mice (alpha-S-tg) would enhance the substantia nigra (SN) pathology resulting from treatment with MPTP. For this purpose, alpha-S-tg mice were produced expressing high levels of wild-type (wt) human alpha-S under the control of the neuron-specific Thy-1 promoter. Alpha-S-tg mice and non-tg controls were treated with MPTP (15 mg/kg ip, twice a week for 2 weeks) or saline (Sal) and then examined 2 weeks after completion of treatment by transmission electron microscopy (EM). We found that alpha-S-tg mice treated with MPTP had extensive mitochondrial alterations, increases in mitochondrial size, filamentous neuritic aggregations, axonal degeneration, and formation of electron dense perinuclear cytoplasmic inclusions in the SN that did not occur in the hippocampus or neocortex, nor in MPTP-treated non-tg mice or Sal-treated alpha-S-tg mice. These findings support the potential involvement of alpha-S expression in the vulnerability of SN neurons to toxicity from mitochondrial complex I inhibitors and the subsequent development of neurodegenerative pathology.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0014-4886
pubmed:author
pubmed:issnType
Print
pubmed:volume
186
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
158-72
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:15026254-1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, pubmed-meshheading:15026254-Animals, pubmed-meshheading:15026254-Antigens, Thy-1, pubmed-meshheading:15026254-Dopamine Agents, pubmed-meshheading:15026254-Dose-Response Relationship, Drug, pubmed-meshheading:15026254-Humans, pubmed-meshheading:15026254-Lewy Bodies, pubmed-meshheading:15026254-Mice, pubmed-meshheading:15026254-Mice, Inbred C57BL, pubmed-meshheading:15026254-Mice, Transgenic, pubmed-meshheading:15026254-Microscopy, Electron, pubmed-meshheading:15026254-Mitochondria, pubmed-meshheading:15026254-Nerve Degeneration, pubmed-meshheading:15026254-Nerve Tissue Proteins, pubmed-meshheading:15026254-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:15026254-Substantia Nigra, pubmed-meshheading:15026254-Synucleins, pubmed-meshheading:15026254-alpha-Synuclein
pubmed:year
2004
pubmed:articleTitle
Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.
pubmed:affiliation
Neurology Service, VA San Diego Healthcare System, San Diego, CA 92161-9127, USA. dsong@vapop.ucsd.edu
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't